Phase 2 confirmatory study of cemiplimab (350 mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6

Brett GM Hughes,¹ Jean-Jacques Grob,² Samantha E Bowyer,³ Fiona Day,⁴ Rahul Ladwa,⁵ Brian Stein,⁶ Eva Muñoz-Couselo,⁷ Nicole Basset-Seguin,⁸ Alexander Guminski,⁹ Laurent Mortier,¹⁰ Axel Hauschild,¹¹ Michael R Migden,¹² Chrysalyne D Schmults,¹³ Suk-Young Yoo,¹⁴ Jocelyn Booth,¹⁴ Frank Seebach,¹⁵ Israel Lowy,¹⁵ Matthew G Fury,¹⁵ Danny Rischin¹⁶

Australia; ⁵Princess Alexandra Hospital, Woolloongabba, Australia; ⁶Adelaide Cancer Centre, Adelaide, Australia; ⁷Vall d'Hebron University Hospital, St Leonards, Australia; ⁷Vall d'Hebron University Hospital, St Leonards, Australia; ⁸ ¹⁰Dermatology Clinic, CARADERM and University of Texas MD Anderson Cancer Center, Houston, TX, USA; ¹³Department of Dermatology, Brigham and Women's Hospital, ¹⁰Dermatology Clinic, CARADERM and University of Texas MD Anderson Cancer Center, Houston, TX, USA; ¹³Department of Dermatology, Brigham and Women's Hospital, ¹⁰Dermatology Clinic, CARADERM and University of Texas MD Anderson Cancer Center, Houston, TX, USA; ¹³Department of Dermatology, Brigham and Women's Hospital, ¹⁰Dermatology Clinic, CARADERM and University of Texas MD Anderson Cancer Center, Houston, TX, USA; ¹³Department of Dermatology, Brigham and Women's Hospital, ¹⁰Department of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA; ¹³Department of Dermatology, Brigham and Women's Hospital, ¹⁰Department of Bermatology, Brigham and Women's Hospital, ¹⁰Department of Bermatology, Brigham and Women's Hospital, ¹⁰Department of Bermatology, ¹⁰Departme Harvard Medical School, Boston, MA, USA; ¹⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; ¹⁶Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Introduction

- CSCC is the second most common malignancy in the US, accounts for 20% of skin cancer cases, and results in 1 million cases per year, with the incidence continuing to rise 50–200% annually within the last three decades.¹
- Surgical excision is most commonly used and provides most patients a favorable prognosis; unfortunately the recurrence rate of CSCC is higher than with other cancers and the development of locally advanced (laCSCC) or metastatic disease (mCSCC) occurs in a number of these cases.^{2,3}
- The discovery of the programmed cell death-1 (PD-1) receptor and its associated ligands programmed cell death-ligand 1 (PD-L1) and programmed cell deathligand 2 (PD-L2) in tumors has offered a new direction for clinical cancer immunotherapies in targeting anti-PD-1/PD-L1.⁴
- Cemiplimab is a high-affinity, fully human, hinge-stabilized immunoglobulin G4 anti-PD-L1 antibody that blocks the interaction of PD-1 receptor with its ligands, PD-L1 and PD-L2.⁵
- In the Phase 1 (NCT02383212) and the pivotal Phase 2 (NCT02760498) clinical trials, cemiplimab was the first systemic therapy to demonstrate significant antitumor activity in patients with advanced CSCC.⁶⁻⁹
- Here, we report additional efficacy and safety data from the pivotal Phase 2 trial that examined the Group 6 patients with advanced CSCC undergoing cemiplimab monotherapy, 350 mg every 3 weeks (Q3W) for up to 108 weeks.

Objective

- The primary objective was to assess the clinical benefits of cemiplimab by measuring the objective response rate (ORR; complete response [CR] + partial response [PR]) per independent central review (ICR).
- The secondary objectives were to report the duration of response (DOR), progression-free survival (PFS), and overall survival (OS) by central and investigator review. Safety and tolerability of cemiplimab are also reported.

Methods

- EMPOWER-CSCC-1 is an open-label, non-randomized, multicenter, international Phase 2 study of patients with advanced CSCC (NCT02760498).
- At data cutoff date of October 25, 2021, 167 patients \geq 18 years old with histologically confirmed metastatic or unresectable laCSCC were enrolled in the study.
- The patients enrolled were treated with cemiplimab 350 mg intravenous or with the option to switch to subcutaneous dosing, for up to 108 weeks.

Results

Patients

- A total of 167 patients were enrolled with a median age of 76.0 years (range, 40–94). Most patients had a primary cancer site of the head and neck (n=113, 67.7%) (Table 1).
- One-hundred-and-sixty-five of 167 patients received at least one dose of cemiplimab and were followed-up for a median of 8.71 months (range, 0.0–19.5). The median duration of exposure was 35.7 weeks (range, 0.9–86.9).
- ORR, CR, and PR analysis were performed with the total number of 164 patients, excluding patients who did not receive cemiplimab (n=2) or had no baseline tumor assessment due to COVID-19 (n=1).
- Five of 167 patients received prior systemic therapies (0.03%).

Characteristic	Advanced CSCC (n=167)
Age, median (range), years	76.0 (40–94)
Male, n (%)	130 (77.8)
ECOG performance status, n (%)	
0	67 (40.1)
1	98 (58.7)
Missing	2 (1.2)
Primary CSCC site: head and neck, n (%)	113 (67.7)
Metastatic CSCC, n (%)	100 (59.9)
Locally advanced CSCC, n (%)	67 (40.1)
Duration of exposure to cemiplimab, median (range), weeks	35.7 (0.9–86.9)
Number of cemiplimab doses administered, median (range)	11.0 (1–29)

Response

- Tumor response per ICR, median PFS, and OS remained generally consistent with the previous update (data cutoff, October 11, 2020) (Table 2).
- The median ORR was 45.1% (74/164; 95% confidence interval [CI], 37.4–53.1) with CR in 5.5% (9/164) and PR in 39.6% (65/164) (**Table 2**).
- As of the data cutoff date of October 25, 2021, the median DOR was not reached (95% CI, 13.0 months-not evaluable [NE]) (Table 2, Figure 1).
- Among treated patients, the median PFS was 14.7 months (95% CI, 10.4–NE) and the median OS was not reached (95% CI, 17.6 months-NE) (Table 2, Figure 2).

Table 2. Tumor response per ICR


	Patients, n	Advanced CSCC cemiplimab: 350 mg Q3W (Group 6)
Duration of follow-up, median (range), months	1 65 ⁺	8.71 (0.0–19.5)
ORR, % (95% CI)	1 64 [‡]	45.1 (37.4–53.1)
CR, n (%)		9 (5.5)
PR, n (%)		65 (39.6)
DOR, median (95% CI), months	74 [§]	NR (13.0–NE)
PFS, median (95% CI), months	1 65 ⁺	14.7 (10.4–NE)
OS, median (95% CI), months	1 65 ⁺	NR (17.6–NE)

[†]Full analysis set: Group 6 patients who received at least one dose of cemiplimab (n=165).


⁺The total number of patients in the tumor response analysis was 164, excluding patients who did not receive cemiplimab (n=2) or had no baseline tumor assessment due to COVID-19 (n=1). [§]Full analysis set: patients with confirmed CR or PR (n=74).

CI, confidence interval; CR, complete response; CSCC, cutaneous squamous cell carcinoma; DOR, duration of response; ICR,

independent central review; NE, not evaluable; NR, not reached; ORR, objective response rate; OS, overall survival; PFS, progressionfree survival; PR, partial response; Q3W, every 3 weeks.



CSCC, cutaneous squamous cell carcinoma; DOR, duration of response; ICR, independent central review; Q3W, every 3 weeks.



Safety

- Of 165 patients that received at least one dose of cemiplimab, 163 (98.8%) experienced at least one treatment-emergent adverse event (TEAE) of any grade regardless of attribution (**Table 3**).
- The most common TEAE of any grade was fatigue (n=43, 26.1%), followed by diarrhea (n=35, 21.2%), pruritus (n=35, 21.2%), and nausea (n=28, 17.0%).
- Grade \geq 3 TEAEs were reported in 75 patients (45.5%), the most common being hypertension (n=6, 3.6%) and pneumonia (n=6, 3.6%), followed by general physical health deterioration (n=5, 3.0%).
- In total, 16 patients (9.7%) experienced at least one Grade \geq 3 immune-related adverse event based on investigator assessment, with the most common being adrenal insufficiency (n=2, 1.2%).
- Overall, 23 patients (13.9%) discontinued treatment due to possibly treatmentrelated TEAEs of any grade, with those resulting in death reported in 14 cases (8.5%) in Group 6.
- None of the deaths were considered to be related to cemiplimab. The fatal AEs were due to: COVID-19-related events (n=2), other infection (n=4), sudden death not otherwise specified without autopsy (n=2), myocardial infarction, gastrointestinal bleed, pulmonary embolism, acute myelogenous leukemia, declining mental status in setting of morphine patient-controlled analgesia and pulmonary edema, and meningitis that was likely infectious (n=1 each).

Table 3. TEAEs [†]					
	Advanced CSCC (n=165)				
TEAEs, n (%)	Any grade	Grade ≥3			
Any	163 (98.8)	75 (45.5)			
Serious	72 (43.6)	57 (34.5)			
Leading to discontinuation	23 (13.9) 12 (7.3)				
Leading to death	14 (8.5) 14 (8.5)				
Any-grade TEAEs occurring in \geq 10% of patients					
Fatigue	43 (26.1)				
Diarrhea	35 (21.2)				
Pruritus	35 (21.2)				
Nausea	28 (17.0)				
Asthenia	23 (13.9)				
Arthralgia	22 (13.3)				
Constipation	19 (11.5)				
Decreased appetite	19 (11.5)				
Rash maculo-papular	17 (10.3)				
Most common Grade ≥3 TEAEs					
Hypertension	6 (3.6)				
Pneumonia	6 (3.6)				
General physical health deterioration	5 (3	.0)			

Adverse events were coded according to the Preferred Terms of the Medical Dictionary for Regulatory Activities, version 22.1. The severity of adverse events was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. CSCC, cutaneous squamous cell carcinoma; TEAE, treatment emergent adverse event.

Conclusions

- Group 6 in the EMPOWER-CSCC-1 study demonstrated a safety and efficacy profile that was consistent with the previously reported clinical trial experience for Groups 1, 2, and 3 of the study.
- Cemiplimab remains a standard-of-care option in patients with advanced CSCC who are not candidates for curative surgery or radiation.

References

1.	Waldman A et al. Hematol Oncol Clin North Am. 2019;33:1–12.	6.	Migden MR et al. <i>Lancet Oncol</i> . 2020;21:294–305.
2.	Que SKT et al. <i>J Am Acad Dermatol</i> . 2018;78:237–247.	7.	Migden MR et al. <i>N Engl J Med</i> . 2018;379:341–351.
3.	Stratigos AJ et al. Eur J Cancer. 2020;128:60–82.	8.	Rischin D et al. J Immunother Cancer. 2021;9.
4.	Sunshine J et al. Curr Opin Pharmacol. 2015;23:32–38.	9.	Rischin D et al. J Immunother Cancer. 2020;8.

Burova E et al. *Mol Cancer Ther*. 2017:16:861–870

Acknowledgments

The authors thank the patients who participated in this study. Medical writing and editorial support under the direction of the authors was provided by Tingting Griffin, PhD, of Prime (Knutsford, UK) and funded by Regeneron Pharmaceuticals, Inc., and Sanofi according to Good Publication Practice guidelines. Responsibility for all opinions, conclusions and data interpretation lies with the authors.

Disclosure

Brett GM Hughes reports serving on an advisory board for Amgen, Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, Sanofi, Eisai, Pfizer, AstraZeneca and Takeda; and research grants from Amgen. Jean-Jacques Grob reports serving on an advisory board for Bristol-Myers Squibb Merck Sharp & Dohme, Novartis, Roche, Amgen, Pierre-Fabre, Philogen, Pfizer, Merck, Sanofi and Amgen; and an advisory role for Bristol-Myers Squibb. Samantha E Bowver reports an advisory board role for Ipsen, Sanofi and Lilly; and virtual meeting sponsorship from Bristol-Myers Squibb and MSD Australia. Fiona Day reports serving on an advisory board for Amgen; and clinical trial support (IMP provision, no financial support) from Bristol-Myers Squibb and AstraZeneca. Rahul Ladwa reports honoraria from Bristol-Myers Squibb, Merck Sharp & Dohme and AstraZeneca; consulting or advisory role for Roche and Astra Zeneca; and travel, accommodations and expenses from Merck Sharp & Dohme Brian Stein reports ownership of stocks/shares in Icon Group. Eva Muñoz-Couselo reports serving on an advisory board for Amgen, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche and Sanofi; honoraria from Amgen, Bristol-Myers Squibb, Merck Sharp & Dohme Novartis, Pierre Fabre and Roche; and clinical trial participation (principal investigator) for Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche and Sanofi. Nicole Basset-Seguin reports serving as an invited speaker, advisory board member and consultant for Regeneron, Sanofi, Sun Pharma and Galderma. Alexander Guminski reports serving on advisory boards for Regeneron, Merck Sharp & Dohme and Pfizer; serving as an invited speaker for Bristol-Myers Squibb; research grant from Sun Pharma; and non-financial (in kind drug supply) research support from AstraZeneca. Laurent Mortier reports personal fees and nonfinancial support from Roche, Novartis, Bristol-Myers Squibb and Merck Sharp & Dohme. Axel Hauschild reports consultancy, paid presentations and study support from Almirall, Amgen, Bristol-Myers Squibb, Merck, Merck Serono, MSD/Merck, Novartis, Neracare, Philogen, Pierre Fabre, Provectus, Regeneron, Replimune, Roche Sanofi and Sun Pharma. Michael R Migden reports advisory roles with honoraria from Regeneron, Sanofi, Replimune and Sun Pharmaceuticals Chrysalyne D Schmults reports research grants and funding from Castle Biosciences, Merck and Regeneron; serving as a consultant for Castle Biosciences, Regeneron, Sanofi and Merck; serving as a member of the Board of Directors of American Society of Dermatologic Surgery; serving on an advisory board (Secretary to ascend to President) of the International Society of Dermatologic Surgery and serving on the Non-Melanoma Skin Panel Chair for the National Comprehensive Cancer Network. Suk-Young Yoo, Jocelyn Booth, Frank Seebach, Israel Lowy and Matthew **G Fury** are employees and shareholders of Regeneron Pharmaceuticals, Inc. **Danny Rischin** reports institutional research grants and funding from Regeneron Pharmaceuticals, Inc., Sanofi, Kura Oncology, Roche, Merck Sharp & Dohme, Bristol-Myers Squibb, GlaxoSmithKline and ALX Oncology; and uncompensated scientific committee and advisory board roles for Merck Sharp & Dohme, Regeneron Pharmaceuticals, Inc., Sanofi and GlaxoSmithKline.